Loading…
Hunan traditional Chinese medicine maker known for classic patent remedies like Liuwei Dihuang Wan sold nationwide.
Hunan traditional Chinese medicine maker known for classic patent remedies like Liuwei Dihuang Wan sold nationwide.
In one line: A Chinese heritage-TCM Nature's Bounty.
Moat: narrow (brand). Centuries-old heritage TCM brand name recognized across Chinese pharmacy retail.
Headquarters: Changsha, Hunan, China · Employees: 3,674
Size Jiuzhitang (000989.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.19B, the 1972nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.39 on 6 Nov 2026.
Performance Over six months the shares fell 13.1%, against -8.1% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 45.9% over the last twelve months (peer median 0.0%); the operating margin is 19.2% (peer median 5.4%).
Valuation It trades at 22.7× forward earnings against a peer median of 15.8× (4th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.3 points above its cost of capital (5.8% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.79B | CN¥2.21B | CN¥2.35B | CN¥2.94B | CN¥3.01B |
| Revenue growth | — | -6% | -20% | -2% | — |
| Gross profit | CN¥1.72B | CN¥1.25B | CN¥1.31B | CN¥1.70B | CN¥1.67B |
| EBITDA | n/a | CN¥374M | CN¥294M | CN¥409M | CN¥394M |
| Net income | CN¥375M | CN¥223M | CN¥216M | CN¥297M | CN¥358M |
| Free cash flow | CN¥644M | CN¥398M | CN¥137M | CN¥48.6M | CN¥441M |
| Capital expenditure | CN¥75.9M | CN¥40.0M | CN¥72.2M | CN¥72.8M | CN¥96.8M |
| Total debt | CN¥52.3M | CN¥136M | CN¥134M | CN¥186M | CN¥127M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jiuzhitang 000989.SZ | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% |
| Dong-E-E-Jiao 000423.SZ | $4.80B | -8% | +8% | 29% | 17.1× | -4.6% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000989.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.6% | -1.1% | 10th lowest of 21 |
| 6-month return | -13.1% | -8.1% | 10th lowest of 21 |
| Distance from 52-week high | -22.6% | -32.3% | 6th highest of 21 |
| Revenue growth (TTM) | +45.9% | 0.0% | 3rd highest of 19 |
| Operating margin | 19.2% | 5.4% | 3rd highest of 20 |
| Forward P/E | 22.7× | 15.8× | 4th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | -3.7% | 4.5% | least demanding of 12 |
| Growth delivered (Del g) | -9.0% | +11.3% | 2nd lowest of 12 |
| Hurdle (Req g minus delivered) | +5.3 pp | -5.5 pp | 4th most demanding of 12 |
| ROIC minus cost of capital | +7.3 pp | -0.7 pp | 2nd highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | n/a | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | n/a | 11.7% | +18.1% |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | n/a | n/a | n/a |